An unfavourable environment weighs on GLOBUS MEDICAL INCO., which sees a downgrade to Slightly Negative
The independent financial analyst theScreener just requalified the general evaluation of GLOBUS MEDICAL INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date March 5, 2021, the closing price was USD 62.14 and its target price was estimated at USD 50.49.Globus Medical is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company provides a portfolio of technologies that are used to treat musculoskeletal conditions of the spine, extremities and pelvis. The company's product categories are: Musculoskeletal Solutions, consisting of implantable devices, biologics, accessories, and surgical instruments used in spinal, orthopedic and neurosurgical procedures; and Enabling Technologies, consisting of computer-assisted intelligent systems designed to improve a surgeon's capabilities and streamline surgical procedures to improve patient care and reduce radiation exposure for all involved.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.